When Katrina Bellavance noticed her seven-week-old baby coughing persistently, she uncovered her infant’s pajamas and observed the skin around the tiny ribs retracting with each challenging breath. This alarming incident occurred in Calgary in 2023, prompting Bellavance to rush her daughter to the hospital.
Her baby was diagnosed with respiratory syncytial virus (RSV) and had to spend several days in the hospital receiving oxygen before recovering. RSV is a common but perilous infection that affects infants’ delicate respiratory systems, causing breathing difficulties, wheezing, lung inflammation, pneumonia, and, in rare instances, death.
Although RSV may not be widely recognized by many families, it is the primary reason for hospitalizations among infants during their first year of life, as stated by Dr. Jesse Papenburg from the Montreal Children’s Hospital.
Fortunately, advancements have been made in preventing severe RSV in newborns, with the introduction of potent monoclonal antibody shots. Real-world data from less than two years of global usage has demonstrated remarkable outcomes.
Medical experts are now focusing on enhancing access and adoption of these shots in Canada to reach more families nationwide.
‘A Significant Breakthrough’
Despite effective vaccines being available for many childhood infections, RSV has persisted as a formidable threat. Dr. Jake Scott from Stanford University School of Medicine highlighted the recent breakthrough in RSV prevention, emphasizing the substantial impact it has made.
Research published in the New England Journal of Medicine revealed that antibody shots reduced infant RSV hospitalizations by over 80%. Additionally, studies indicated that vaccinating pregnant mothers, although less effective, still provided considerable protection to infants.
The implementation of RSV prevention measures has been hailed as one of the most substantial advancements in respiratory virus prevention in decades.
Notable reductions in RSV admissions were reported in Madrid, Spain, with around 90% fewer hospitalizations, and in Chile, with a decrease of approximately three-quarters. In Quebec, a universal infant antibody shot program prevented more than half of the usual RSV-related hospitalizations and ICU admissions.
Frontline healthcare providers noted a significant reduction in patient volumes, alleviating the strain RSV typically imposes on pediatric healthcare systems.
Varying Access and Usage Across Canada
During the previous season, Canada introduced a range of RSV shots, including options for pregnant women and older adults, along with nirsevimab, a one-time antibody shot safeguarding infants throughout the RSV season.
However, the rollout of these shots varied across the country initially and continues to exhibit inconsistencies over a year later. Some provinces have implemented universal antibody shot programs, while others, such as British Columbia, Alberta, New Brunswick, and Newfoundland and Labrador, only offer covered shots to high-risk infants.
Ontario stands out as the sole province funding both the antibody shot for all infants and the maternal vaccine. Data from the initial year of the program indicated that nearly 70% of newborns in Ontario received nirsevimab at birth before being discharged from healthcare facilities.
Despite these efforts, uptake rates varied widely among hospitals, ranging from 32% to 90%.
Challenges in Achieving Comprehensive Coverage
Dr. Jeffrey Pernica from McMaster University highlighted the effectiveness of RSV prevention products but emphasized the complexities involved in the rollout process.
Data from Ontario revealed that the primary reason for infants not receiving the shot was parental refusal. Additionally, challenges related to birth timing posed obstacles, particularly for babies born in spring or summer needing shots in the fall.
Physicians have expressed concerns about the need for broader access to RSV shots, citing discrepancies in provincial approaches. In British Columbia and Alberta, plans for expanding antibody shots beyond high-risk infants are under review for future seasons.
Ensuring widespread immunization is crucial due to the prevalence of RSV infections in infants’ first year of life. Dr. Cora Constantinescu from the University of Calgary emphasized the importance of equitable access and transparency regarding the costs of regional RSV immunization programs.
Economic Impact of RSV Infections
Recent research conducted at the University of British Columbia and BC Children’s Hospital Research Institute highlighted the substantial costs associated with infant RSV infections compared to preventive measures.
The study revealed that infants under six months accounted for a significant portion of RSV-related hospital admissions and contributed substantially to the annual cost of RSV hospitalizations. The expenses varied widely, with costs ranging from $8,000 for regular admissions to over
